BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou C, Zhou HJ, Zhang XF, Lou LL, Ye QH, Zheng Y, Wang J, Zhu HT, Dong QZ, Jia HL, Zhu WW, Guo L, Zhao Y, Gao DM, Qin LX. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma. Ann Surg Oncol 2013;20:929-37. [PMID: 23203407 DOI: 10.1245/s10434-012-2749-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Sun T, Li P, Sun D, Bu Q, Li G. Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12954. [PMID: 30412113 DOI: 10.1097/MD.0000000000012954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
2 Zapf MA, Kothari AN, Weber CE, Arffa ML, Wai PY, Driver J, Gupta GN, Kuo PC, Mi Z. Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma. Surgery 2015;158:1039-47; discussion 1047-8. [PMID: 26189955 DOI: 10.1016/j.surg.2015.06.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
3 Rychlíková J, Vecka M, Jáchymová M, Macášek J, Hrabák P, Zeman M, Vávrová L, Řoupal J, Krechler T, Ák A. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis. Cancer Biomark 2016;17:55-65. [PMID: 27314293 DOI: 10.3233/CBM-160617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
4 Liao M, Sun J, Zhang Q, Tang C, Zhou Y, Cao M, Chen T, Hu C, Yu J, Song Y, Li M, Liao W, Zhou Y. A Novel Post-Operative ALRI Model Accurately Predicts Clinical Outcomes of Resected Hepatocellular Carcinoma Patients. Front Oncol 2021;11:665497. [PMID: 34295811 DOI: 10.3389/fonc.2021.665497] [Reference Citation Analysis]
5 Wong K, Xu Z, Chen J, Lee NP, Luk JM. Circulating markers for prognosis of hepatocellular carcinoma. Expert Opinion on Medical Diagnostics 2013;7:319-29. [DOI: 10.1517/17530059.2013.795146] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
6 Cheng J, Wang W, Sun C, Li M, Wang B, Lv Y. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol 2014;48:806-14. [PMID: 24247813 DOI: 10.1097/MCG.0000000000000018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
7 Wen Y, Jeong S, Xia Q, Kong X. Role of Osteopontin in Liver Diseases. Int J Biol Sci 2016;12:1121-8. [PMID: 27570486 DOI: 10.7150/ijbs.16445] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
8 Strehlow F, Bauer S, Martus P, Weller M, Roth P, Schlegel U, Seidel S, Scheibenbogen C, Korfel A, Kreher S. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. J Neurooncol 2016;129:165-71. [PMID: 27294357 DOI: 10.1007/s11060-016-2162-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
9 Kawai T, Yasuchika K, Ishii T, Miyauchi Y, Kojima H, Yamaoka R, Katayama H, Yoshitoshi EY, Ogiso S, Kita S, Yasuda K, Fukumitsu K, Komori J, Hatano E, Kawaguchi Y, Uemoto S. SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma. Sci Rep. 2016;6:30489. [PMID: 27457505 DOI: 10.1038/srep30489] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
10 Nagoshi S. Osteopontin: Versatile modulator of liver diseases. Hepatol Res. 2014;44:22-30. [PMID: 23701387 DOI: 10.1111/hepr.12166] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
11 Kang YS, Jeong EJ, Seok HJ, Kim SK, Hwang JS, Choi ML, Jo DG, Kim Y, Choi J, Lee YJ, Jung E, Min JK, Han TS, Kim JS. Cks1 regulates human hepatocellular carcinoma cell progression through osteopontin expression. Biochem Biophys Res Commun 2019;508:275-81. [PMID: 30497779 DOI: 10.1016/j.bbrc.2018.11.070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Ng L, Wan TM, Lam CS, Chow AK, Wong SK, Man JH, Li HS, Cheng NS, Pak RC, Cheung AH, Yau TC, Lo OS, Foo DC, Poon JT, Poon RT, Pang RW, Law WL. Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer. PLoS One 2015;10:e0126219. [PMID: 25961724 DOI: 10.1371/journal.pone.0126219] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
13 Zhu Y, Gao XM, Yang J, Xu D, Zhang Y, Lu M, Zhang Z, Sheng YY, Li JH, Yu XX, Zheng Y, Dong QZ, Qin LX. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma. Cancer Sci 2018;109:710-23. [PMID: 29285854 DOI: 10.1111/cas.13487] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
14 Qin L. Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies. Front Med. 2014;8:24-32. [PMID: 24464486 DOI: 10.1007/s11684-014-0312-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
15 Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E, Llamas-Gutierrez F, Meunier B, Boudjema K, Clément B. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology. 2013;58:1992-2000. [PMID: 23775819 DOI: 10.1002/hep.26577] [Cited by in Crossref: 77] [Cited by in F6Publishing: 125] [Article Influence: 8.6] [Reference Citation Analysis]
16 Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol 2014;37:131-41. [PMID: 24657887 DOI: 10.1016/j.matbio.2014.03.001] [Cited by in Crossref: 140] [Cited by in F6Publishing: 140] [Article Influence: 17.5] [Reference Citation Analysis]